To all our CKB CORE users, don’t miss the latest new features now available! Register for a free CORE account here and then login for access. Feel free to contact us at ckbsupport@genomenon.com if you have any questions!

Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04484623
Title Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma (DREAMM 8)
Acronym DREAMM 8
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors GlaxoSmithKline
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA | TUR | POL | NZL | ITA | ISR | GRC | GBR | FRA | ESP | DEU | CZE | BRA | AUS

Facility Status City State Zip Country Details
GSK Investigational Site Tucson Arizona 85712 United States Details
GSK Investigational Site Fort Myers Florida 33901 United States Details
GSK Investigational Site Boston Massachusetts 02215 United States Details
GSK Investigational Site Kansas City Missouri 64132 United States Details
GSK Investigational Site Nashville Tennessee 37203 United States Details
GSK Investigational Site Garran Australian Capital Territory 2605 Australia Details
GSK Investigational Site Darlinghurst New South Wales 2010 Australia Details
GSK Investigational Site Gosford NSW New South Wales 2250 Australia Details
GSK Investigational Site Port Macquarie New South Wales 2444 Australia Details
GSK Investigational Site Benowa Queensland 4217 Australia Details
GSK Investigational Site South Brisbane Queensland 4101 Australia Details
GSK Investigational Site Adelaide South Australia 5000 Australia Details
GSK Investigational Site Fitzroy Victoria 3065 Australia Details
GSK Investigational Site Heidelberg Victoria 3084 Australia Details
GSK Investigational Site Malvern Victoria 3144 Australia Details
GSK Investigational Site Nedlands Western Australia 6009 Australia Details
GSK Investigational Site Curitiba 01308-050 Brazil Details
GSK Investigational Site Joinville 89201-260 Brazil Details
GSK Investigational Site Porto Alegre 90035-903 Brazil Details
GSK Investigational Site SAo Paulo 04537-081 Brazil Details
GSK Investigational Site Beijing 100191 China Details
GSK Investigational Site Beijing China Details
GSK Investigational Site Changchun 130012 China Details
GSK Investigational Site Changsha 410013 China Details
GSK Investigational Site Hangzhou 310003 China Details
GSK Investigational Site Jiangsu 221004 China Details
GSK Investigational Site Nanchang 330006 China Details
GSK Investigational Site Shenyang 110004 China Details
GSK Investigational Site Tianjin 300020 China Details
GSK Investigational Site Brno 62500 Czechia Details
GSK Investigational Site Hradec Kralove 50333 Czechia Details
GSK Investigational Site Praha 2 12808 Czechia Details
GSK Investigational Site Marseille 13273 France Details
GSK Investigational Site Toulouse cedex 9 31059 France Details
GSK Investigational Site Vanduvre-lEs-Nancy 54511 France Details
GSK Investigational Site Mainz 55131 Germany Details
GSK Investigational Site Tuebingen 72076 Germany Details
GSK Investigational Site Wuerzburg 97080 Germany Details
GSK Investigational Site Athens 10676 Greece Details
GSK Investigational Site Athens 115 25 Greece Details
GSK Investigational Site Athens 115 28 Greece Details
GSK Investigational Site Ioannina 45 500 Greece Details
GSK Investigational Site Thessaloniki 57010 Greece Details
GSK Investigational Site Haifa 3109601 Israel Details
GSK Investigational Site Jerusalem 91031 Israel Details
GSK Investigational Site Kfar Saba 4428164 Israel Details
GSK Investigational Site Nahariya 2633737 Israel Details
GSK Investigational Site Petach-Tikva 4941492 Israel Details
GSK Investigational Site Tel Aviv 6423906 Israel Details
GSK Investigational Site Bologna 40138 Italy Details
GSK Investigational Site Milano 20122 Italy Details
GSK Investigational Site Pavia 27100 Italy Details
GSK Investigational Site Roma 00161 Italy Details
GSK Investigational Site Aichi 467-8602 Japan Details
GSK Investigational Site Chiba 277-8567 Japan Details
GSK Investigational Site Chiba 296-8602 Japan Details
GSK Investigational Site Ehime 790-8524 Japan Details
GSK Investigational Site Fukushima 960-1295 Japan Details
GSK Investigational Site Gunma 371-8511 Japan Details
GSK Investigational Site Gunma 377-0280 Japan Details
GSK Investigational Site Hokkaido 060-8648 Japan Details
GSK Investigational Site Iwate 028-3695 Japan Details
GSK Investigational Site Okayama 701-1192 Japan Details
GSK Investigational Site Osaka 565-0871 Japan Details
GSK Investigational Site Tottori 683-8504 Japan Details
GSK Investigational Site Yamagata 990-9585 Japan Details
GSK Investigational Site Gyeonggi-do 10408 Korea, Republic of Details
GSK Investigational Site Hwasun 58128 Korea, Republic of Details
GSK Investigational Site Inchon 21565 Korea, Republic of Details
GSK Investigational Site Seoul 03080 Korea, Republic of Details
GSK Investigational Site Seoul 03722 Korea, Republic of Details
GSK Investigational Site Seoul 06351 Korea, Republic of Details
GSK Investigational Site Seoul 06591 Korea, Republic of Details
GSK Investigational Site Auckland 2025 New Zealand Details
GSK Investigational Site Dunedin 9016 New Zealand Details
GSK Investigational Site Grafton 1023 New Zealand Details
GSK Investigational Site Hamilton 3204 New Zealand Details
GSK Investigational Site Takapuna Auckland 622 New Zealand Details
GSK Investigational Site Tauranga 3143 New Zealand Details
GSK Investigational Site Bydgoszcz 85-168 Poland Details
GSK Investigational Site Gdansk 80-214 Poland Details
GSK Investigational Site Krakow 31-501 Poland Details
GSK Investigational Site Lodz 93-513 Poland Details
GSK Investigational Site Wroclaw 50-367 Poland Details
GSK Investigational Site Moscow 125101 Russian Federation Details
GSK Investigational Site Moscow 125284 Russian Federation Details
GSK Investigational Site Novosibirsk 630087 Russian Federation Details
GSK Investigational Site Saint Petersburg 197341 Russian Federation Details
GSK Investigational Site Samara 443099 Russian Federation Details
GSK Investigational Site Sochi 354057 Russian Federation Details
GSK Investigational Site St Petersburg 191024 Russian Federation Details
GSK Investigational Site St-Petersburg 194291 Russian Federation Details
GSK Investigational Site Barcelona 08036 Spain Details
GSK Investigational Site Barcelona 8035 Spain Details
GSK Investigational Site Gijon 33204 Spain Details
GSK Investigational Site L'Hospitalet De Llobrega 08908 Spain Details
GSK Investigational Site Madrid 28006 Spain Details
GSK Investigational Site Madrid 28027 Spain Details
GSK Investigational Site MOstoles Madrid 28933 Spain Details
GSK Investigational Site Murcia 30008 Spain Details
GSK Investigational Site Palma de Mallorca 07120 Spain Details
GSK Investigational Site PamplonaNavarra 31008 Spain Details
GSK Investigational Site Pozuelo De AlarcOn Madr 28223 Spain Details
GSK Investigational Site Salamanca 37007 Spain Details
GSK Investigational Site Sevilla 41013 Spain Details
GSK Investigational Site Valencia 46026 Spain Details
GSK Investigational Site Ankara 06100 Turkey Details
GSK Investigational Site Ankara 6340 Turkey Details
GSK Investigational Site Ankara 6560 Turkey Details
GSK Investigational Site Izmir 35100 Turkey Details
GSK Investigational Site Izmir 35330 Turkey Details
GSK Investigational Site Kocaeli 41400 Turkey Details
GSK Investigational Site Mersin 33343 Turkey Details
GSK Investigational Site Samsun 55139 Turkey Details
GSK Investigational Site London W12 0HS United Kingdom Details
GSK Investigational Site Plymouth PL6 8D8 United Kingdom Details
GSK Investigational Site Southampton SO16 6YD United Kingdom Details
GSK Investigational Site Stoke on Trent ST4 6QG United Kingdom Details
GSK Investigational Site Sutton SM2 5PT United Kingdom Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field